Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group.
We determined the reporting rates for adverse events following the administration of inactivated mouse-brain derived Japanese encephalitis vaccine (JEV) based on post-marketing surveillance data from Japan and the United States. The rate of total adverse events per 100,000 doses was 2.8 in Japan and 15.0 in the United States. In Japan, 17 neurological disorders were reported from April 1996 to October 1998 for a rate of 0.2 per 100,000 doses. In the United States, no serious neurological adverse events temporally associated with JEV were reported from January 1993 to June 1999. Rates for systemic hypersensitivity reactions were 0.8 and 6.3 per 100,000 doses in Japan and the United States, respectively. Passively collected VAERS surveillance data indicate that characteristic hypersensitivity reactions with a delayed onset continue to occur among JEV recipients and that conservative recommendations limiting its use to travelers at high risk of infection with Japanese encephalitis are appropriate.
Takahashi
H
H
Epidemic Intelligence Service, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
Pool
V
V
Tsai
T F
TF
Chen
R T
RT
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004664:Encephalitis Virus, Japanese / Q000276:immunology*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007564:Japan; D011358:Product Surveillance, Postmarketing; D014481:United States; D014611:Vaccination; D014765:Viral Vaccines / Q000009:adverse effects*
D014765:Viral Vaccines